Literature DB >> 9448556

Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection.

J Hayashi1, Y Kishihara, K Ueno, K Yamaji, Y Kawakami, N Furusyo, Y Sawayama, S Kashiwagi.   

Abstract

BACKGROUND: Interferon alfa is used widely for patients with chronic hepatitis C virus (HCV) infection. Little is known, however, of the relationship between patients' sex and the effectiveness of interferon alfa treatment in these patients.
METHODS: We treated 311 patients (199 men and 112 women) with human lymphoblastoid interferon (6 million units subcutaneously every day for 2 weeks and 3 times a week for 22 weeks) and observed them for an additional 6 months. Serum HCV RNA levels and genotype were tested by polymerase chain reaction before treatment. A liver biopsy was also done. For the purposes of this study, a complete response was defined as the elimination of HCV RNA for at least 6 months after the termination of treatment.
RESULTS: The rate of complete response was 27.1% for men and 24.1% for women. With multiple logistic regression analysis, the HCV RNA level (P < .001), genotype (P < .001), patients' sex (P < .05), and the interaction between sex and age were associated with a complete response to interferon alfa. The rate of complete response was 33.3% in men aged 39 years and younger, 25.0% in men aged 40 years and older. 75.0% in women aged 39 years and younger, and 15.6% in women aged 40 years and older. The odds ratio by group was 1.00, 0.72, 4.38, and 0.21, respectively.
CONCLUSIONS: Our finding that women aged 39 years and younger are responsive to interferon alfa treatment suggests that hormonal activity, in particular the level of estrogen, may be associated with the sustained elimination of HCV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448556     DOI: 10.1001/archinte.158.2.177

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  23 in total

Review 1.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 2.  Mechanisms of HCV survival in the host.

Authors:  Ella H Sklan; Prista Charuworn; Philip S Pang; Jeffrey S Glenn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

3.  Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.

Authors:  Norihiro Furusyo; Jun Hayashi; Kenichiro Kashiwagi; Hisashi Nakashima; Shigeki Nabeshima; Yasunori Sawayama; Naoko Kinukawa; Seizaburo Kashiwagi
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

4.  Strenuous physical labor is important as a cause of elevated alanine aminotransferase levels in Japanese patients with chronic hepatitis C viremia.

Authors:  Norihiko Kubo; Norihiro Furusyo; Hisashi Nakashima; Kenichiro Kashiwagi; Jun Hayashi
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

5.  Clinical course of chronic hepatitis C virus infection is not influenced by concurrent hepatitis G virus infection.

Authors:  J Hayashi; K Ueno; Y Kawakami; Y Kishihara; I Ariyama; N Furusyo; Y Sawayama; Y Etoh; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

6.  Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

Authors:  N Furusyo; J Hayashi; M Ohmiya; Y Sawayama; Y Kawakami; I Ariyama; N Kinukawa; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

7.  Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.

Authors:  Hitomi Sezaki; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2008-10-28       Impact factor: 3.199

8.  Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Taniai; Shigeru Otaguro; Mosaburo Kainuma; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  BMC Gastroenterol       Date:  2010-04-16       Impact factor: 3.067

9.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

10.  A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.

Authors:  Muhammad Idrees; Sheikh Riazuddin
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.